retatrutide trial data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Today, we shared new data

Tirzepatide works by activating receptors for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) hormones

D-Phe7 substitution introduces a D-amino acid configuration at position 7, sterically hindering peptidase access and extending biological activity in preclinical models

Description Additional information Description FOXO4-DRI Peptide Vial **Important Information: Each peptide comes lyophilized/freeze-dried and must be reconstituted with Bacteriostatic Water in order to be dispensable in liquid form

This 5mg vial provides a small research supply of HPLC-verified, high-purity BPC-157, ideal for short pilot studies

It has helped change the lives of hundreds of individuals who were able to go back to their active lifestyles after treatment

Water, stabilizer polydextrose, acidity regulator citric acid, carbon dioxide, cola emulsion (flavouring, colouring E 150d), L-carnitine, taurine, preservatives (potassium sorbate, sodium benzoate), sweeteners (acesulfame K, sucralose), caffeine